Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

A1340000

Atenolol

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H22N2O3
Numéro CAS:
29122-68-7
Poids moléculaire :
266.34
Numéro CE :
249-451-7
Numéro MDL:
MFCD00057645
Code UNSPSC :
41116107
ID de substance PubChem :
329770360
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

atenolol

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

Clé InChI

METKIMKYRPQLGS-UHFFFAOYSA-N

Informations sur le gène

human ... ADRB1(153)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Atenolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1044403

Atenolol, United States Pharmacopeia (USP) Reference Standard

Y0001089

Atenolol for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1909

Atenolol, Pharmaceutical Secondary Standard; Certified Reference Material

BP370

Atenolol impurity standard, British Pharmacopoeia (BP) Reference Standard

BP492

Atenolol, British Pharmacopoeia (BP) Reference Standard

1044367

Atenolol Related Compound F, United States Pharmacopeia (USP) Reference Standard

1044265

Atenolol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044254

Atenolol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044276

Atenolol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044298

Atenolol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1044287

Atenolol Related Compound D, United States Pharmacopeia (USP) Reference Standard

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
H Sakurai et al.
Japanese circulation journal, 64(11), 893-896 (2000-12-08)
Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration
Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Sonia A Tabacova et al.
Reproductive toxicology (Elmsford, N.Y.), 16(1), 1-7 (2002-04-06)
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
Afficher tous les articles scientifiques apparentés

Articles

TLC Silica Gel 60 G Plates with Gypsum

TLC plates, with silica gel, gypsum as binder, International Pharmacopoeia compliant, for identification of Atenolol and Chlorthalidone in tablets

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique